Join

Compare · MDT vs NXL

MDT vs NXL

Side-by-side comparison of Medtronic plc. (MDT) and Nexalin Technology Inc. (NXL): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MDT and NXL operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
  • MDT is the larger of the two at $105.19B, about 9466.2x NXL ($11.1M).
  • Over the past year, MDT is down 6.2% and NXL is down 59.3% - MDT leads by 53.1 points.
  • MDT has been more active in the news (18 items in the past 4 weeks vs 4 for NXL).
  • MDT has more recent analyst coverage (25 ratings vs 0 for NXL).
PerformanceMDT-6.20%NXL-59.31%
2025-06-05+0.00%2026-06-05
MetricMDTNXL
Company
Medtronic plc.
Nexalin Technology Inc.
Price
$81.63-0.35%
$0.48-4.93%
Market cap
$105.19B
$11.1M
1M return
+5.19%
+37.60%
1Y return
-6.20%
-59.31%
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Exchange
NYSE
NASDAQ
IPO
2022
News (4w)
18
4
Recent ratings
25
0
MDT

Medtronic plc.

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Latest MDT

Latest NXL